Strategic Clinical Expansion Bolsters Tenax Therapeutics’ Path to Approval Tenax Therapeutics is expanding its Phase 3 LEVEL study for TNX-103 in PH-HFpEF, increasing patient enrollment to 230 and boosting statistical power. The FDA has reviewed and cleared this updated plan, while a second global Phase 3 trial, LEVEL-2, is set to begin this year. Funding now extends operations through 2027.12